Safety and efficacy of ipilimumab alone or in combination with anti-PD-1 (IPI+PD1) in patients with metastatic melanoma resistant to PD1 monotherapy
Latest Information Update: 10 Jun 2020
At a glance
- Drugs Ipilimumab (Primary) ; Programmed cell death-1 ligand-1 inhibitors
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 10 Jun 2020 New trial record